Navigation Links
King and Pain Therapeutics Announce REMOXY(R) NDA Update
Date:7/7/2009

BRISTOL, Tenn. and SAN MATEO, Calif., July 7 /PRNewswire-FirstCall/ -- King Pharmaceuticals, Inc. (NYSE: KG) and Pain Therapeutics, Inc. (Nasdaq: PTIE) today announced that on July 2, 2009, King met with the US Food and Drug Administration (FDA) to discuss the Complete Response Letter regarding the New Drug Application (NDA) for REMOXY(R). The outcome of this meeting provided King with a clear path forward to resubmit the REMOXY(R) NDA and to address all FDA comments in the Complete Response Letter.

King now anticipates the resubmission of the NDA could occur mid-year 2010. The Company believes the rate-limiting step is the generation of six-month stability data, and no new clinical trials are required. King remains committed to the development and commercialization of REMOXY(R), and looks forward to working closely with the FDA toward approval of the product.

About REMOXY(R)

REMOXY, an investigational drug, is a unique, long-acting oxycodone formulation for moderate-to-severe chronic pain designed to reduce potential risks of unintended use. In mid-2008, an NDA for REMOXY was accepted by the FDA and was granted Priority Review. In December 2008, Pain Therapeutics received a Complete Response Letter from the FDA. Subsequent to the receipt of the Complete Response Letter, King assumed full control of all activities related to the development of REMOXY(R).

About King Pharmaceuticals, Inc.

King, headquartered in Bristol, Tennessee, is a vertically integrated branded pharmaceutical company. King, an S&P 500 Index company, seeks to capitalize on opportunities in the pharmaceutical industry through the development, including through in-licensing arrangement
'/>"/>

SOURCE King Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cell Therapeutics Added to Russell 3000(R), Russell 2000(R) and Russell Global(R) Indexes
2. Yaupon Therapeutics Completes Patient Enrollment for Pivotal Phase 2 Study of Clearazide for Treatment of Cutaneous T-cell Lymphoma
3. Horizon Therapeutics Names Dr. Jeffrey W. Sherman Executive Vice President and Chief Medical Officer
4. PTC Therapeutics Receives $2.6 Million in Government Grants
5. Cell Therapeutics on Preliminary List of Additions to Russell 3000(R) Index and Russell Global(R) Index
6. Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Chief Medical Officer
7. CSL Limited and Talecris Biotherapeutics Agree to Terminate Merger Agreement
8. Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions
9. Orexigen(R) Therapeutics Presents Additional NB-302 Contrave(R) Data at American Diabetes Association (ADA) 69th Scientific Sessions
10. Tobira Therapeutics Inc. Announces Key Addition to Scientific Advisory Board
11. PeriCor Therapeutics Reports Positive Preclinical Results of GP531 at the European Heart Failure Congress in Nice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... , Sept. 23, 2014 ... of the biomaterial family and are increasingly becoming ... body fluids and tissues without having a negative ... used as tissue replacement and tissue repair materials ... materials such as ceramics, glass, glass-ceramics, and composites. ...
(Date:9/23/2014)... Kamal Rashid , PhD, director of ... Center (BETC) and research professor of biology and biotechnology ... an international two-day event focused on biomanufacturing set for ... the event will bring together leaders of companies from ... and produce human therapeutics. “The growth curve for biomanufacturing ...
(Date:9/23/2014)... 2014 This is a professional ... the Phenolic Resin industry in Global and China.The ... including definitions, applications and industry chain structure. Global ... provided with a focus on history, developments, trends ... between the international and Chinese situation is also ...
(Date:9/23/2014)... de Reuil, France (PRWEB) September 23, 2014 ... to protection of laboratory personnel since 1968 and Burdinola, ... the development of a new filtered fume hood. ... above their laboratory fume hood, Burdinola will now offer ... for filtering a wide range of chemicals, best-in-class detection ...
Breaking Biology Technology:Global Bioactive Material Market 2014-2018 2Worcester Polytechnic Institute's Biomanufacturing Expertise to be Featured in Berlin 2Worcester Polytechnic Institute's Biomanufacturing Expertise to be Featured in Berlin 3Phenolic Resin Industry (International, China) Development Policy and Plan Now Available at ReportsnReports.com 2Erlab Partners with Burdinola to Deliver an Innovative Filtered Fume Hood 2
... , RESTON, Va., July 9 Mirixa Corporation, the ... the hiring of three new members to its growing ... FASCP, Kim Swiger, RPh, and Paul Miller, MS, RPh. ... closely with Mirixa,s pharmacy partners, state and national pharmacy ...
... FRANCISCO, Calif., July 9 Poniard Pharmaceuticals, Inc. (Nasdaq: ... therapies, today announced the appointment of Gary A. Lyons, to ... number of directors on the Poniard board to ten. , ... to help guide us as we move toward our goal ...
... , SUNNYVALE, Calif., July 9 Cepheid (Nasdaq: CPHD ... second quarter ended June 30, 2009, on Thursday, July 30, 2009, ... will host a management presentation at 2 p.m. Pacific Time on ... the live webcast, please visit Cepheid,s website at www.cepheid.com/investors ...
Cached Biology Technology:Mirixa Corporation Announces Key New Hires 2Poniard Pharmaceuticals Appoints Gary A. Lyons to Board of Directors 2Poniard Pharmaceuticals Appoints Gary A. Lyons to Board of Directors 3Cepheid Schedules 2009 Second Quarter Financial Results Announcement and Webcast 2
(Date:9/23/2014)... Scientists have scoured cow rumens and termite guts for ... for the production of next-generation biofuels, but some of ... human lower intestine, researchers report. , Their study ... Academy of Sciences , is the first to use ... the human gut can digest fiber, breaking it down ...
(Date:9/23/2014)... could be as good for your mental as your ... by the University of Warwick,s Medical School using data ... BMJ Open focused on mental wellbeing and ... associated with an individual,s fruit and vegetable consumption. , ... or more portions of fruit and vegetables a day, ...
(Date:9/23/2014)... organisms, including humans, have parasitic DNA fragments called "jumping ... instructions in the process. And that phenomenon can result ... the University of Rochester now report that the "jumping ... when a multi-function protein stops keeping them in check ... In a study published today in Nature Communications ...
Breaking Biology News(10 mins):Search for better biofuels microbes leads to the human gut 2Search for better biofuels microbes leads to the human gut 3Eating five a day may keep the blues away 2A multi-function protein is key to stopping genomic parasites from 'jumping' 2
... replacement surgeries can help relieve joint pain common ... the debris from prosthetic joints leads to aseptic ... a Wayne State University researcher determined that the ... disintegration. There was one caveat, however: there are ...
... female mosquito cannot tell if the male that she has ... her eggs, according to a new study from scientists at ... journal Proceedings of the National Academy of Sciences , ... of malaria by interfering with the mosquitoes, ability to reproduce. ...
... ALAMOS, New Mexico, August 8, 2011A Los Alamos National ... the first time the critical role that an elusive ... aid in treatment of peptic ulcers or acid reflux ... waste into transportation fuels. In a paper appearing ...
Cached Biology News:Wayne State researcher discovers antibiotic useful for localized treatment of bone wear 2Mosquitoes can't spot a spermless mate 2Mosquitoes can't spot a spermless mate 3Researchers use neutrons to spy on the elusive hydronium ion 2
HAMP Immunogen: HAMP (AAH20612, 25 a.a. ~ 85 a.a) full length recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
... peptide transporter 2 (APT2) ... transporter PSF2) (Peptide supply ... transporter involved in antigen ... Antigen: ...
Raised to arginine vasopressin coupled to bovine thyroglobulin with carbodiimide ....
Chicken polyclonal to HAGH ( Abpromise for all tested applications). Antigen: Synthetic peptide, corresponding to N terminal amino acids 110-260 of Human HAGH. Entrez GeneID: 3029 Swiss ...
Biology Products: